Cystitis treatment with high dose chondroitin sulfate

Abstract

Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.

We claim:  
     
         1 . A method for treating a patient afflicted with a bladder or urinary tract condition selected from cystitis and a related condition for which only or more cystitis symptoms are elicited in the afflicted patient upon instillation of a potassium chloride solution, comprising the step of delivering to the patient by instillation a composition comprising an aqueous vehicle, and chondroitin sulfate in a unit dose of at least 250 mgs.  
     
     
         2 . A method according to  claim 1 , wherein said composition comprises chondroitin. sulfate at a dose in the range from 300 mgs to 800 mgs.  
     
     
         3 . A method according to  claim 2 , wherein said composition comprises chondroitin sulfate at a dose in the range from 350 to 500 mgs.  
     
     
         4 . A method according to  claim 3 , wherein said composition comprises chondroitin sulfate at a dose of 400 mgs.  
     
     
         5 . A method according to  claim 1 , wherein said aqueous vehicle is present at a volume of from 1 mL to 250 mL.  
     
     
         6 . A method according to  claim 2 , wherein said aqueous vehicle is present at a volume of from 10 mL to 100 mL.  
     
     
         7 . A method according to  claim 3 , wherein said aqueous vehicle is present a a volume of from 20 mL to 40 mL.  
     
     
         8 . A method according to  claim 1 , wherein said composition comprises 400 mg of chondroitin sulfate in 20 mL of aqueous vehicle.  
     
     
         9 . A method according to  claim 1 , wherein the aqueous vehicle is phosphate-buffered saline vehicle.  
     
     
         10 . A method according to  claim 1 , for the treatment of cystitis.  
     
     
         11 . A method according to  claim 1 , for the treatment of interstitial cystitis.  
     
     
         12 . A method according to  claim 1 , wherein said composition is delivered to said patient at least one weekly for a period of at least 6 weeks.  
     
     
         13 . The method according to  claim 12 , wherein said composition is delivered to said patient twice weekly for a period of at least six weeks.  
     
     
         14 . A pharmaceutical composition adapted for instillation to the bladder of a patient, the composition comprising chondroitin sulfate in an amount from 250 mgs to 1200 mgs, and an aqueous vehicle in a volume of from 10 mL to 100 mL.  
     
     
         15 . A pharmaceutical composition) according to  claim 14 , wherein the aqueous vehicle is present in a volume of from 10 mL to 40 mL.  
     
     
         16 . A pharmaceutical composition according to  claim 15 , wherein the chondroitin sulfate is present in an amount of from 350 mgs to 600 mgs.  
     
     
         17 . A pharmaceutical composition according to  claim 14 , comprising 400 mgs of chondroitin sulfate in 20 mL of an aqueous vehicle.  
     
     
         18 . A pharmaceutical composition according to  claim 17 , wherein the aqueous vehicle is phosphate buffered saline.  
     
     
         19 . A kit useful clinically for performing the method of  claim 1 , the kit comprising, in combination, 
 (1) a composition comprising an aqueous vehicle, and chondroitin sulfate in a unit dose of at least 250 mgs; and    (2) printed instructions teaching the use of said composition in accordance with the method of  claim 1.